Form D · Other
PETCURE ONCOLOGY LLC
Chicago, IL · CIK 0001632708
Offering snapshot reported Aug 10, 2016 · SEC filing
- Reported sold
- $1.75M Offering amount: $3.5M
- Investors reported
- 17 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Jul 26, 2016 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 10, 2016 | Initial | $1,750,000 | No comparison | 17 | SEC filing |
| Jul 27, 2015 | Amendment | $4,000,000 | $725,000vs Feb 18, 2015 | 18 | SEC filing |
| Feb 18, 2015 | Initial | $3,275,000 | No comparison | 12 | SEC filing |
Offering details
- Securities
- Equity, Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $1.25K
- Finders' fees
- $0
- Form D file number
- 021-268611
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| TRESTLE POINT, LLC | 138494 |
Source: Form D, filed Aug 10, 2016. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Scott Milligan | Executive |
Issuer details
Industry: Other (See others in industry)
Address:
8770 West Bryn Mawr Suite 1370
Chicago, IL, 60631
Chicago, IL, 60631